Marc Hirschfeld1,2,3, Gerta Rücker2,4, Daniela Weiß1,2, Kai Berner1,2, Andrea Ritter1,2, Markus Jäger1,2, Thalia Erbes5,6. 1. Department of Obstetrics and Gynecology, Medical Center, University of Freiburg, Freiburg, Germany. 2. Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3. Institute of Veterinary Medicine, Georg-August-University Goettingen, Goettingen, Germany. 4. Institute of Medical Biometry and Statistics, Medical Center, University of Freiburg, Freiburg, Germany. 5. Department of Obstetrics and Gynecology, Medical Center, University of Freiburg, Freiburg, Germany. thalia.erbes@uniklinik-freiburg.de. 6. Faculty of Medicine, University of Freiburg, Freiburg, Germany. thalia.erbes@uniklinik-freiburg.de.
Abstract
INTRODUCTION: Breast cancer (BC) is the most frequent malignant disease in women worldwide and is therefore challenging for the healthcare system. Early BC detection remains a leading factor that improves overall outcome and disease management. Aside from established screening procedures, there is a constant demand for additional BC detection methods. Routine BC screening via non-invasive liquid biopsy biomarkers is one auspicious approach to either complete or even replace the current state-of-the-art diagnostics. The study explores the diagnostic potential of urinary exosomal microRNAs with specific BC biomarker characteristics to initiate the potential prospective application of non-invasive BC screening as routine practice. METHODS: Based on a case-control study (69 BC vs. 40 healthy controls), expression level quantification and subsequent biostatistical computation of 13 urine-derived microRNAs were performed to evaluate their diagnostic relevance in BC. RESULTS: Multilateral statistical assessment determined and repeatedly confirmed a specific panel of four urinary microRNA types (miR-424, miR-423, miR-660, and let7-i) as a highly specific combinatory biomarker tool discriminating BC patients from healthy controls, with 98.6% sensitivity and 100% specificity. DISCUSSION: Urine-based BC diagnosis may be achieved through the analysis of distinct microRNA panels with proven biomarker abilities. Subject to further validation, the implementation of urinary BC detection in routine screening offers a promising non-invasive alternative in women's healthcare.
INTRODUCTION:Breast cancer (BC) is the most frequent malignant disease in women worldwide and is therefore challenging for the healthcare system. Early BC detection remains a leading factor that improves overall outcome and disease management. Aside from established screening procedures, there is a constant demand for additional BC detection methods. Routine BC screening via non-invasive liquid biopsy biomarkers is one auspicious approach to either complete or even replace the current state-of-the-art diagnostics. The study explores the diagnostic potential of urinary exosomal microRNAs with specific BC biomarker characteristics to initiate the potential prospective application of non-invasive BC screening as routine practice. METHODS: Based on a case-control study (69 BC vs. 40 healthy controls), expression level quantification and subsequent biostatistical computation of 13 urine-derived microRNAs were performed to evaluate their diagnostic relevance in BC. RESULTS: Multilateral statistical assessment determined and repeatedly confirmed a specific panel of four urinary microRNA types (miR-424, miR-423, miR-660, and let7-i) as a highly specific combinatory biomarker tool discriminating BCpatients from healthy controls, with 98.6% sensitivity and 100% specificity. DISCUSSION: Urine-based BC diagnosis may be achieved through the analysis of distinct microRNA panels with proven biomarker abilities. Subject to further validation, the implementation of urinary BC detection in routine screening offers a promising non-invasive alternative in women's healthcare.
Authors: Sebastian L Hofbauer; Michela de Martino; Ilaria Lucca; Andrea Haitel; Martin Susani; Shahrokh F Shariat; Tobias Klatte Journal: Urol Oncol Date: 2018-10-12 Impact factor: 3.498
Authors: Xiao-Feng Le; Maria I Almeida; Weiqun Mao; Riccardo Spizzo; Simona Rossi; Milena S Nicoloso; Shu Zhang; Yun Wu; George A Calin; Robert C Bast Journal: PLoS One Date: 2012-07-19 Impact factor: 3.240
Authors: Julia Beretov; Valerie C Wasinger; Ewan K A Millar; Peter Schwartz; Peter H Graham; Yong Li Journal: PLoS One Date: 2015-11-06 Impact factor: 3.240
Authors: Susana I S Patuleia; Elsken van der Wall; Carla H van Gils; Marije F Bakker; Agnes Jager; Marleen M Voorhorst-Ogink; Paul J van Diest; Cathy B Moelans Journal: Cell Oncol (Dordr) Date: 2021-10-16 Impact factor: 7.051